Paolo Barone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Paolo Barone has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Maria Di Gregorio
Department of Neurology and Stroke, Ospedali Riuniti San Giovanni di Dio e Ruggi d’Aragona, Salerno, Italy
2 shared publications - Alfredo Siani
Department of Diagnostic and Interventional Neuroradiology, Ospedali Riuniti San Giovanni di Dio e Ruggi d’Aragona, Salerno, Italy
1 shared publication - Aniello Iovino
Department of Neurology and Stroke, Ospedali Riuniti San Giovanni di Dio e Ruggi d’Aragona, Salerno, Italy
1 shared publication - Antonio Romanelli
Department of Anesthesia and Intensive Care, Ospedali Riuniti San Giovanni di Dio e Ruggi d’Aragona, Salerno, Italy
1 shared publication Beatrice D’aRco
Neurology Unit, University Hospital “San Giovanni di Dio e Ruggi d’Aragona”, Salerno, Italy
1 shared publication- Caterina Giordano
Univ Salerno, Surg & Dent Scuola Med Salernitana, Dept Med, Neurosci Sect, Via Allende 43, I-84081 Baronissi, SA, Italy
1 shared publication
Latest Publications
- 26 July 2025
- Published by Springer Nature in Neuroradiology
- Vol. 67 (9) , 2519-2526
Pegasus stent as a rescue therapy in large vessel occlusions with underlying intracranial atherosclerosis: a retrospective Single-Center experience
Purpose Large vessel occlusions (LVOs) due to underlying intracranial atherosclerotic disease (ICAD) are associated with higher rates of mechanical thrombectomy (MT) failure and worse clinical outcomes. The pEGASUS-HPC stent is a novel low-profile device with a hydrophilic polymer coating designed to reduce thrombogenicity. Evidence regarding its use in ICAD-related LVOs is currently limited. Methods We conducted a retrospective single-center study to evaluate the safety and efficacy of the pEGASUS-HPC stent as a rescue treatment following MT failure in ICAD-related LVOs. Results From December 2022 to December 2024 among 393 thrombectomies performed, 25 patients met the inclusion criteria. The mean age was 66 years (53–90) and 18/25 (72%) were men. The anterior circulation was involved in most cases (17/25, 68%). Median baseline NIHSS was 8 and ASPECTS was 9. Rescue stenting was performed due to persistent occlusion (28%), residual stenosis (56%), or early reocclusion (16%). Final TICI 2b–3 recanalization was achieved in 92% of cases. Pre-stenting angioplasty was performed in 32% and post-stenting in 16% of cases. Periprocedural complications occurred in 16% of patients. Median NIHSS at 24 h was 5 and the median ASPECTS was 8. At 24 h, only 1/25 patients demonstrate in-stent thrombosis. Long-term follow-up (6 months) was available for 76% of patients; stent patency was maintained in all, and 84% achieved a favorable outcome (mRS < 2 at 90 days). Conclusion Rescue stenting with the pEGASUS-HPC stent in selected cases of ICAD-related LVO appears to be a feasible and effective treatment option after MT failure, with high recanalization rates, favorable clinical outcomes, and acceptable complication rates.
- 26 July 2025
- Published by Springer Nature in Neuroradiology
- Vol. 67 (9) , 2519-2526
Pegasus stent as a rescue therapy in large vessel occlusions with underlying intracranial atherosclerosis: a retrospective Single-Center experience
Purpose Large vessel occlusions (LVOs) due to underlying intracranial atherosclerotic disease (ICAD) are associated with higher rates of mechanical thrombectomy (MT) failure and worse clinical outcomes. The pEGASUS-HPC stent is a novel low-profile device with a hydrophilic polymer coating designed to reduce thrombogenicity. Evidence regarding its use in ICAD-related LVOs is currently limited. Methods We conducted a retrospective single-center study to evaluate the safety and efficacy of the pEGASUS-HPC stent as a rescue treatment following MT failure in ICAD-related LVOs. Results From December 2022 to December 2024 among 393 thrombectomies performed, 25 patients met the inclusion criteria. The mean age was 66 years (53–90) and 18/25 (72%) were men. The anterior circulation was involved in most cases (17/25, 68%). Median baseline NIHSS was 8 and ASPECTS was 9. Rescue stenting was performed due to persistent occlusion (28%), residual stenosis (56%), or early reocclusion (16%). Final TICI 2b–3 recanalization was achieved in 92% of cases. Pre-stenting angioplasty was performed in 32% and post-stenting in 16% of cases. Periprocedural complications occurred in 16% of patients. Median NIHSS at 24 h was 5 and the median ASPECTS was 8. At 24 h, only 1/25 patients demonstrate in-stent thrombosis. Long-term follow-up (6 months) was available for 76% of patients; stent patency was maintained in all, and 84% achieved a favorable outcome (mRS < 2 at 90 days). Conclusion Rescue stenting with the pEGASUS-HPC stent in selected cases of ICAD-related LVO appears to be a feasible and effective treatment option after MT failure, with high recanalization rates, favorable clinical outcomes, and acceptable complication rates.
- 27 December 2023
- Published by Springer Nature in Neurological Sciences
- Vol. 45 (6) , 2807-2810
Bariatric surgery and dimethyl fumarate-induced lymphopenia in patients with multiple sclerosis
Introduction Lymphopenia is a known side effect of dimethyl fumarate (DMF), a disease-modifying therapy (DMT) for patients with multiple sclerosis (pwMS). A body mass index ≥ 30 kg/m2 has been identified as a protective factor; however, no data are available on lymphopenia in pwMS undergoing to weight loss due to bariatric surgery. Methods We described two pwMS with history of bariatric surgery who started DMF as DMT. Results The two pwMS experienced persistent lymphopenia during DMF-treatment, which was resolved after its discontinuation. Conclusions Several mechanisms might modify DMF pharmacokinetic profiles after bariatric surgery and its bioavailability. Absolute lymphocyte count should be monitored in pwMS treated with DMF and history of bariatric surgery and weight loss.
- 27 December 2023
- Published by Springer Nature in Neurological Sciences
- Vol. 45 (6) , 2807-2810
Bariatric surgery and dimethyl fumarate-induced lymphopenia in patients with multiple sclerosis
Introduction Lymphopenia is a known side effect of dimethyl fumarate (DMF), a disease-modifying therapy (DMT) for patients with multiple sclerosis (pwMS). A body mass index ≥ 30 kg/m2 has been identified as a protective factor; however, no data are available on lymphopenia in pwMS undergoing to weight loss due to bariatric surgery. Methods We described two pwMS with history of bariatric surgery who started DMF as DMT. Results The two pwMS experienced persistent lymphopenia during DMF-treatment, which was resolved after its discontinuation. Conclusions Several mechanisms might modify DMF pharmacokinetic profiles after bariatric surgery and its bioavailability. Absolute lymphocyte count should be monitored in pwMS treated with DMF and history of bariatric surgery and weight loss.